氨溴特罗口服液治疗婴幼儿支气管肺炎的临床效果

Clinical effect of ambroxol oral liquid in the treatment of infantile bronchopneumonia

目的探讨氨溴特罗口服液治疗婴幼儿支气管肺炎的临床效果。方法将90例婴幼儿支气管肺炎患儿根据随机数字表法分为对照组和观察组,各45例。在常规病因治疗的基础上,对照组给予盐酸氨溴索颗粒治疗,观察组给予氨溴特罗口服液治疗。比较两组患儿的临床疗效、血清炎症因子指标及免疫球蛋白指标。结果观察组的治疗总有效率高于对照组(P<0.05)。治疗后,两组患儿的CRP、IL-6、PCT水平均低于治疗前,且观察组低于对照组(P<0.05)。治疗后,两组患儿的IgG、IgA、IgM水平均高于治疗前,且观察组高于对照组(P<0.05)。结论氨溴特罗口服液用于婴幼儿支气管肺炎治疗中具有良好的临床效果。

Objective To explore the clinical effect of ambroxol oral liquid in the treatment of infantile bronchopneumonia. Methods Ninety infants with bronchopneumonia were divided into control group and observation group according to random number table method, with 45 cases in each group. On the basis of routine etiological treatment, the control group was treated with ambroxol hydrochloride granules, while the observation group was treated with ambroxol oral liquid. The clinical effect, and levels of serum inflammatory factors and immunoglobulin between the two groups were compared. Results The total effective rate of treatment in the observation group was higher than that in the control group (P<0.05). After treatment, the levels of CRP, IL-6 and PCT in the two groups were lower than those before treatment, and those in the observation group were lower than the control group (P<0.05). After treatment, the levels of IgG, IgA and IgM in the two groups were higher than those before treatment, and those in the observation group were higher than the control group (P<0.05). Conclusion Ambroxol oral liquid has good clinical efficacy in the treatment of infantile bronchopneumonia.